Amantadine News and Research

RSS

Exploring the neuroprotective potential of cell-penetrating peptides, extracellular vesicles, and micro ribonucleic acids

In a recent review published in Biomedicines, researchers explored extracellular vesicles (EVs), cell-penetrating peptides (CPPs), and micro ribonucleic acids (miRNAs) as therapies for neurodegenerative diseases such as Alzheimer’s disease (AD) and Parkinson’s disease (PD).

1 Mar 2023

Delay in consciousness in severe cases of COVID-19 may be caused by neural hibernation

An article published in the journal PNAS provides a conceptual analysis to interpret the brain state of coronavirus disease 2019 (COVID-19) patients experiencing prolonged recovery of consciousness.

10 Nov 2022

A review of emerging pediatric respiratory viruses

Respiratory viruses continue to be a leading cause of childhood morbidity and mortality.

26 Oct 2022

Researchers report aminoadamantanes that block SARS-CoV-2 infection by S-nitrosylation of the host ACE2 protein

Researchers investigated the use of aminoadamantane nitrate compounds as anti-SARS-CoV-2 drugs.

3 Oct 2022

S-Nitrosylation of ACE2 inhibits binding of SARS-CoV-2 spike protein

In a recent study posted to the bioRxiv* preprint server, researchers developed aminoadamantane nitrates compounds that inhibit the ion channels formed by the envelope (E) protein of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and enable targeted drug delivery of nitric oxide (NO)-related group for S-nitrosylation of host angiotensin-converting enzyme 2 (ACE2), which would inhibit ACE2 binding with the viral spike (S) protein and thereby inhibit viral replication in the host.

11 Apr 2022

Comparison of COVID-19 and influenza-associated complications

Researchers compare the number, types, and risk for complications among COVID-19 and influenza patients using claims data.

9 Jan 2022

MIT researchers unravel the molecular structure of key coronavirus protein

MIT chemists have determined the molecular structure of a protein found in the SARS-CoV-2 virus. This protein, called the envelope protein E, forms a cation-selective channel and plays a key role in the virus's ability to replicate itself and stimulate the host cell's inflammation response.

12 Nov 2020

Insufficient evidence for cognitive efficacy of drug treatments in multiple sclerosis

Researchers at Kessler Foundation conducted a comprehensive review of pharmacologic agents used in the treatment of multiple sclerosis, seeking evidence for efficacy for the cognitive dysfunction experienced by more than half of affected individuals.

17 Jun 2020

Experimental drug offers hope for improving movement symptoms of Parkinson's

Results from a study looking at an experimental drug to tackle the debilitating side effect of dyskinesia, have offered hope that it may have potential as a future treatment for people with Parkinson's.

2 Mar 2020

Medicinal cannabis substitute may help unlock new treatment for Parkinson's disease

A drug that provides the benefits obtained from medicinal cannabis without the "high" or other side effects may help to unlock a new treatment for Parkinson's disease.

19 Dec 2019

Novel clinical trial to examine use of cannabidiol in people with Parkinson's-related psychosis

A pioneering clinical trial will investigate the use of cannabidiol (CBD) - a compound found in the cannabis plant - in people with Parkinson's-related psychosis.

14 Oct 2019

New guideline released to improve diagnosis, care for people with prolonged disorders of consciousness

For people in a vegetative or minimally conscious state caused by brain injury, an accurate diagnosis and ongoing medical and rehabilitative care based on the latest scientific evidence could mean a better chance for recovery, according to a new guideline by the American Academy of Neurology, American Congress of Rehabilitation Medicine and the National Institute on Disability, Independent Living, and Rehabilitation Research.

9 Aug 2018

NIST chemists publish new data on important compound’s thermodynamic properties

Amantadine hydrochloride may be the most common medication you've never heard of. This compound has been around for decades as the basis for antiviral and other medications, from flu therapy to treatments for brain disorders such as Parkinson's disease and the fatigue associated with multiple sclerosis.

2 May 2017

Researchers synthetize molecules to block virus that causes influenza A

The influenza A virus is a contagious and severe respiratory infection that affects animals but also humans. Researchers from the University of Barcelona have synthetized some molecules which are able to block the virus that causes influenza A and some of the mutations that make it resistant to common drugs.

7 Nov 2014

Kansas State University's research shows promise to fight novel avian H7N9 influenza virus

The novel avian H7N9 influenza virus has caused more than 130 human infections with 43 deaths in China. New research, conducted under the supervision of Kansas State University's Juergen Richt, is showing promise in helping to fight this deadly virus.

17 Jan 2014

New research shows promise in helping combat novel drug-resistant H7N9 influenza virus

16 Jan 2014

New drug-resistant strain of bird flu appears to retain ability to cause serious disease in humans

Researchers at the Icahn School of Medicine at Mount Sinai reported that a virulent new strain of influenza - the virus that causes the flu - appears to retain its ability to cause serious disease in humans even after it develops resistance to antiviral medications. The finding was included in a study that was published today in the journal Nature Communications.

12 Dec 2013

Adamas Pharmaceuticals reports positive results from ADS-5102 Phase 2/3 EASED clinical trial

Adamas Pharmaceuticals, Inc. presented positive results today from the Phase 2/3 EASED clinical trial of ADS-5102 at the World Parkinson's Congress. ADS-5102 is Adamas' proprietary long-acting capsule formulation of amantadine HCl in development for the treatment of levodopa-induced dyskinesia in Parkinson's disease patients.

2 Oct 2013

Some strains of avian H7N9 influenza develop resistance to antiviral drugs

Some strains of the avian H7N9 influenza that emerged in China this year have developed resistance to the only antiviral drugs available to treat the infection, but testing for antiviral resistance can give misleading results, helping hasten the spread of resistant strains.

17 Jul 2013

Safinamide improves responder rates in fluctuating Parkinson's patients in Phase III study

Newron Pharmaceuticals S.p.A. ("Newron"), a research and development company focused on novel CNS and pain therapies, and its partner Zambon S.p.A., a pharmaceutical company strongly committed to the respiratory, primary care and CNS therapeutic areas, presented results from SETTLE Phase III study with safinamide at the 17th International Congress of Parkinson's disease and Movement Disorders, taking place from June 16 to 20, 2013, at the Sydney Convention and Exhibition Centre, Sydney, Australia.

19 Jun 2013